MyFinsight
Home
Blog
About
Contact
Download
Download image
Non Us
$11M
US
$216M
Non Us
$171M
US
$159M
Non Us
$105M
US
$147M
Non Us
$36M
US
$13M
Non Us
$55M
US
$47M
Non Us
$92M
US
$31M
Non Us
$41M
US
$275M
Non Us
$152M
US
$96M
Non Us
$275M
US
$376M
Revenue From Contract
With Customer...
$23M
Collaboration revenues
$45M
Non Us
$21M
US
$152M
Non Us
$372M
US
$327M
Collaboration revenues-Non Us
$205M
US
$512M
Non Us
$4M
US
$48M
Non Us
$77M
US
$18M
Non Us
$79M
US
$42M
Non Us
$33M
US
$227M
Non Us
$8M
US
$310M
Non Us
$155M
US
$788M
Non Us
$2M
US
$903M
Non Us
$370M
US
$766M
Non Us
$591M
US
$1,485M
Non Us
$590M
US
$3,801M
Other Products
$657M
Linzess
Constella-Other Key Products
$227M
Creon-Other Key Products-US
$378M
MAVYRET-Other Key Products
$329M
Eye Care-Other Eye
Care
$252M
Alphagan Combigan-Eye
Care
$49M
Eye Care-Lumigan
Ganfort
$103M
Eye Care-Ozurdex
$123M
Aesthetics-Other Aesthetics
$316M
Aesthetics-Juvederm Collection
$248M
Aesthetics-Botox Cosmetic
$651M
Oncology-Other Oncology-US
$8M
Epkinly-Oncology
$68M
Elahere-Oncology
$173M
Oncology-VENCLEXTA
$698M
Imbruvica-Oncology
$717M
Neuroscience-Other Neuroscience
$52M
Duodopa-Neuroscience
$95M
Neuroscience-Vyalev
$121M
Neuroscience-Qulipta
$259M
Neuroscience-Ubrelvy
$318M
Botox
Therapeutic-Neuroscience
$942M
Neuroscience-Vraylar
$905M
HUMIRA-Immunology
$1,135M
Immunology-RINVOQ
$2,076M
Immunology-SKYRIZI
$4,391M
Net revenues
$16,618M
Operating earnings
$4,544M
Total operating costs
and expenses
$12,074M
Other operating
income
$109M
Earnings before income
tax expense
$2,668M
Other expense, net
-$1,210M
Net foreign
exchange loss
-$11M
Interest expense, net
-$655M
Acquired ipr&d and
milestones
$1,265M
Research and development
$2,579M
Selling, general and
administrative
$3,895M
Cost of products sold
$4,552M
Net earnings
attributable to...
-$1M
Net earnings
$1,815M
Income tax expense
(benefit)
$853M
Net earnings
attributable to abbvie inc
$1,816M
Back
Back
Income Statement
source: myfinsight.com
ABBV_BIG copy-svg
AbbVie Inc. (ABBV)
ABBV_BIG copy-svg
AbbVie Inc. (ABBV)